

## DAFTAR PUSTAKA

- Achmad, S. A., 2007, *Tumbuhan-Tumbuhan Obat Indonesia*, ITB, Bandung.
- Afifah, E. dan Lentera, T., 2003, *Khasiat dan Manfaat Temulawak : Rimpang Penyembuh Aneka Penyakit*, PT.Agro Media Pustaka, Jakarta.
- Aggarwal BB, Sung B. 2009. Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. *Trends Pharmacol Sci.* 2009;**30**(2):85–94. doi: 10.1016/j.tips.2008.11.002. [PubMed] [Cross Ref]
- Aggarwal B, 2009, Potential Therapeutic Effects of Curcumin, the Anti-inflammatory Agent, Against Neurodegenerative, Cardiovascular, Pulmonary, Metabolic, Autoimmune and Neoplastic Diseases, *Int J Biochem Cell Biol.*; **41**(1): 40-50
- Ahsan, H., Parveen, N., Khan, N.U., and Hadi, S.M., 1999, Pro-oxidant, anti-oxidant and cleavage activities on DNA of curcumin and its derivatives demethoxycurcumin and bisdemethoxycurcumin, *Chem.-Biol. Interact.*, **121**, 161-175.
- Alcocer-Varela J, Iglesias A, Llorente L, Alarcon-Segovia D, 1985, Effects of L-canavanine on T cells may explain the induction of systemic lupus erythematosus by alfalfa. *Arthritis Rheum.* Jan;**28**(1):52-7.
- Alessandri C, Cristiana Barbati, Davide Vacirca, Paola Piscopo, Annamaria Confaloni, Massimo Sanchez, et al, 2012, T lymphocytes from patients with systemic lupus erythematosus are resistant to induction of autophagy, *FASEB J.* **26**, 4722–4732 (2012). [www.fasebj.org](http://www.fasebj.org)
- Al-Karawi D, Al Mamoori DA, Tayyar Y. 2016, The role of curcumin administration in patients with major depressive disorder: mini meta-analysis of clinical trials. *Phytother Res.*; **30**(2):175-183  
<https://www.ncbi.nlm.nih.gov/pubmed/26610378>
- Amissah-Arthur MB dan Gordon C, 2010, Contemporary Treatment of Systemic Lupus Erythematosus, an update for Clinician, *Ther Adv Chronic Dis.*; **1**(4): 163–175. doi: 10.1177/2040622310380100  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3513867/>
- Anand P, Kunnumakkara AB, Robert A. Newman and Bharat B. Aggarwal, 2007, Bioavailability of Curcumin: Problems and Promise, *Mol. Pharmaceutics*, **4** (6), pp 807–818 (PubMed)

- Ansari, M.J., Ahmad, S., Kohli, K., Ali, J., and Khar, R.K., 2005, Stability-indicating HPTLC determination of curcumin in bulk drug and pharmaceutical formulations, *J.Pharm Biomed Anal*, **39**, 132-138.
- Aringer M, Smolen J. 2008, The role of tumor necrosis factor-alpha in systemic lupus erythematosus. *Arthritis Res Ther.*; **10**(1):202. [PMC free article][PubMed]
- Al Tahan, F.J., 2012. Exploration of Antinociceptive, Antipyretic and AntiInflammatory Activities of Curcumin in Male Rat. *Iraqi Journal of Science*. **53** : 786-93.
- Bachen EA, Chesney MA, Criswell LA, 2009, Prevalence of mood and anxiety disorders in women with systemic lupus erythematosus. *Arthritis Rheum.* Jun 15; **61**(6):822-9.
- Badan Pengawas Obat dan Makanan Republik Indonesia. 2001, Pedoman Cara Uji Klinik yang Baik (CUKB) di Indonesia, hal 82
- Badan Pengawas Obat dan Makanan Republik Indonesia. 2005. *Info POM*. **6** (6) : 1-12.
- Badsha H, Kong KO, Lian TY, Chan SP, Edwards CJ, Ching HH, 2002, Low-dose pulse methylprednisolone for systemic lupus erythematosus flares is efficacious and has a decreased risk of infectious complications, *Lupus*. 2002;11(8):508-13.
- Banerjee S, Sarkar RN, Mullick OS. 2013, A cross-sectional study to assess the association of systemic lupus erythematosus disease activity with levels of high sensitivity C-reactive protein. *Indian J Rheumatol.*; **8**:61-64
- Barbhaiya M, Costenbader KH, 2014, Ultraviolet radiation and Systemic Lupus Erythematosus, *Lupus*, May; **23**(6):588-95. doi: 10.1177/0961203314530488 <https://www.ncbi.nlm.nih.gov/pubmed/24763542>
- Barr SG, Zonana-Nacach A, Magder LS, Petri M., 1999, Patterns of disease activity in systemic lupus erythematosus. *Arthritis Rheum* ; **42**:2682-8.
- Bengtsson, Rylander, Hagmar, Nived dan Sturfelt, 2001, Risk factors for developing systemic lupus erythematosus: a case-control study in southern Sweden, *Oxford J Med & Health Rheuma* Volume **41**, Issue 5 Pp. 563-571

- Bergman J, Miodownik C, Bersudsky Y, et al.2013, Curcumin as an add-on to antidepressive treatment: a randomized, double-blind, placebo-controlled, pilot clinical study. *Clin Neuropharmacol.*; **36**(3):73–77 (PubMed)
- Birmingham DJ, Brad H. Rovin, Ganesh Shidham, Michael Bissell, Haikady N. Nagaraja, and Lee A. Hebert, 2008, Relationship between Albuminuria and Total Proteinuria in Systemic Lupus Erythematosus Nephritis: Diagnostic and Therapeutic Implications, *Clin J Am Soc Nephrol.* Jul; **3**(4): 1028–1033.  
doi: 10.2215/CJN.04761107  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2440287/>
- Black GS, and Tyler JA, 2006, Lessons on Lupus in the Eye, *Review of Optometry*,  
<https://www.reviewofoptometry.com/article/lessons-on-lupus-in-the-eye>
- Bluestein HG. 1992, *The central nervous system in systemic lupus erythematosus*. In: Lahita RG, ed. Systemic lupus erythematosus, 2nd ed. New York: Churchill Livingstone,:639-40.
- Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. 1992, Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. *Arthritis Rheum.* ;**35**:630–40.
- Boswell J dan Schur PH. 1989, Monocyte function in systemic lupus erythematosus. *Clin Immunol Immunopathol.* Aug; **52**(2):271-8.
- Brigham, J. S. 1991. *Social Psychology Second Edition*. New York : Harper Collins Publiiser New York
- Cannon M, 2015, Mycophenolate Mofetil (CellCept) and Mycophenolate Sodium (Myfortic),
- Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P .2003, Morbidity and mortality in systemic lupus erythematosus during a 10-year period, a comparison of early and late manifestation in a cohort of 1000 patients. *Medicine* ;**82**:299-308
- Chainani, N. 2003, Safety and anti-inflammatory activity of curcumin: A component of turmeric (*Curcuma longa*), *J. Altern Compl. Med.* Feb **9**(1) :161-68
- Chan, M.M., 1995, Inhibition of Tumor Necrosis Factor by curcumin: A component of turmeric (*Curcuma longa*). *J. Compl. Med.* **9**(1):161-68.
- Chang X, Wang Li, Jing Li, Dian-shui Wu, 2016, Analysis of anti-depressant

potential of curcumin against depression induced male albino wistar rats,  
*Brain research* 1642 · March 2016. DOI: 10.1016/j.brainres.2016.03.010

Chandran B, Goel A, 2012, A Randomized, Pilot Study to Assess the Efficacy and Safety of Curcumin in Patients with Active Rheumatoid Arthritis, *Phytother. Res* (2012) Published online in Wiley Online Library (wileyonlinelibrary.com) DOI: 10.1002/ptr.4639

Chaiamnuay S, Lomaratana V, Sumransurp S, et al. 2009, Health-related quality of life and disease severity of SLE patients in Phramongkutklao Hospital.. *J Med Assoc Thai*. Nov; **93** Suppl 6:S125-30  
<http://www.ncbi.nlm.nih.gov/pubmed/21280525>

Chaiamnuay S, Bertoli AM, Fernández M, Apte M, Vilá LM, LUMINA Study Group *et al.* 2007, The impact of increased body mass index on systemic lupus erythematosus. *J of Clin Rheumatology*; **13**(3):128-33.

Chattopadhyay, I., Biswas, K., Bandyopadhyay, U., & Benerjee, R., 2004, Tumeric and Curcumin : Biological action and medicinal application, *Current Science*, Vol **87**, No.1, 45-46.

Chehab G, Carnarius H, Schneider M. 2014, What matters for lupus patients? *Presse Med.* 2014 Jun;43(6 Pt 2):e197-207. doi: 10.1016/j.lpm.2014.03.004. Epub May **10.1016/j.lpm.2014.03.004**

Chosdu, R., Mellawati, J., dan Yumiarti., 2004, *Identifikasi Kandung Unsur Makro dan Mikro Dalam Temulawak (Curcuma xanthorrhiza Roxb.)*, Prosiding Seminar Nasional XXV Tumbuhan Obat Indonesia, Tawamangu.

Cho JW, Lee KS, Kim CW. 2007, Curcumin attenuates the expression of IL-1beta, IL-6, and TNF- alpha as well as cyclin E in TNF-alpha-treated HaCaT cells; NF-kappaB and MAPKs as potential upstream targets. *Int J Mol Med*. ;**19**(3):469-74.

Chung WY, Park JH, Kim MJ, Kim HO, Hwang JK, Lee SK, Park KK, 2007,. Xanthorrhizol inhibits 12-O-tetradecanoylphorbol-13-acetate-induced acute inflammation and two-stage mouse skin carcinogenesis by blocking the expression of ornithine decarboxylase, cyclooxygenase-2 and inducible nitric oxide synthase through mitogen-activated protein kinases and/or the nuclear factor-κB. *Carcinogenesis*, **28**(6):1224-1231

Cohly H.H.P., Taylor A., Angel M.F., Salahudeen A.K., 1998, Effect of turmeric,

turmerin and curcumin on H<sub>2</sub>O<sub>2</sub>-induced renal epithelial (LLC-PKI) cell injury. *Free Radic Biol Med.* ;**24**:49–54.  
<https://www.ncbi.nlm.nih.gov/pubmed/9436613>

Cooper GS, Parks CG, Treadwell EL, St Clair EW, Gilkeson GS, Cohen PL, Roubey LAS, Dooley MA, **2002**, Differences by race, sex and age in the clinical and immunologic features of recently diagnosed systemic lupus erythematosus patients in the southeastern United States, *Lupus* vol. **11** no. **3** 161-167

Costallat LT, Coimbra AM, 1994, Systemic lupus erythematosus: clinical and laboratory aspects related to age at disease onset., *Clin and Exper Rheum*, **12**(6):603-607]

Costenbader KH, Feskanich D, Stampfer MJ, Karlson EW, 2007, Reproductive and menopausal factors and risk of systemic lupus erythematosus in women. *Arthritis Rheum.* Apr; **56**(4):1251-62.

Crispin, J. C., Liossis, S. N., Kis-Toth, K., Lieberman, L. A., Kyttaris, V. C., Juang, Y. T., and Tsokos, G. C. ,2010, Pathogenesis of human systemic lupus erythematosus: recent advances. *Trends Mol. Med.* **16**, 47–57

Dall'Era, 2011, Mycophenolate mofetil in the treatment of systemic lupus erythematosus, *Curr Opin Rheumatol.* 2011 Sep; **23**(5):454-8. doi: 10.1097/BOR.0b013e328349a1e5.

Devaraj S<sup>a</sup>, Esfahany AS, Sabariah Ismail<sup>1</sup>, Surash Ramanathan, and Yam Mun Fei, 2010, Evaluation of the Antinociceptive Activity and Acute Oral Toxicity of standardized ethanolic extract of *Curcuma xanthorrhiza* Roxb. *Molecules* **15**, 2925-2934; doi:10.3390/molecules15042925

Devaraj S<sup>b</sup>, Sabariah Ismail<sup>1</sup>, Surash Ramanathan, Santhini Marimuthu and Yam Mun Fei, 2010, Evaluation of the hepatoprotective activity of standardized ethanolic extract of *Curcuma xanthorrhiza* Roxb., *J of Medicin Plants Research* Vol. **4**(**23**), pp. 2512-2517, 4 December, Available online at <http://www.academicjournals.org/JMPR>

Dias SS, Isenberg DA, 2014, Advances in systemic lupus erythematosus, *Medicine* **42**:3, Elsevier

Dobkins PL, Da Costa D, Fortin PR, Edworthy SE, Barr S, Esdaile JM, et al, Living with lupus: a prospective pan-Canadian study. *The J of Rheumatol* vol. **28** no. **11** 2442-2448

- Dulbeco P dan Savarino V, 2013, Therapeutic potential of curcumin in digestive diseases, *World J Gastroenterol*. Dec 28; **19**(48): 9256–9270.  
doi: [10.3748/wjg.v19.i48.9256](https://doi.org/10.3748/wjg.v19.i48.9256)  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3882399/>
- Durcan L , Petri M.,2016, , Immunomodulators in SLE: Clinical evidence and immunologic actions, *Journ of Autoimmun* xxx **1**e12
- Ehrenfeld M, Penchas S, Eliakim M, 1977, Case report Thrombocytosis in rheumatoid arthritis Recurrent arterial thromboembolism and death, *Annals of the Rheumatic Diseases*, **36**, 579-581
- El-Habibi ESME, Azza M El-Wakf1 and Abdullah Mogall, 2013, Efficacy of Curcumin in Reducing Risk of Cardiovascular Disease in High Fat Diet-Fed Rats, *J Bioanal Biomed* , **5**:3 <https://www.omicsonline.org/efficacy-of-curcumin-in-reducing-risk-of-cardiovascular-disease-in-high-fat-diet-fed-rats-1948-593X.1000082.php?aid=16486>
- Feng CS, Ng MH, Szeto RS, Li EK.1991, Bone marrow findings in lupus patients With pancytopenia. *Pathology*. Jan;**23**(1):5-7.
- FitzGerald JD and Grossman JM. 2009,Validity and reliability of retrospective assessment of disease activity and flare in observational cohorts of lupus patients. *Lupus* ;**8**:638-44
- Franklin SS, Milagros J. Jacobs, Nathan D. Wong, Gilbert J. L’Italien and Pablo Lapuerta, 2001, Predominance of Isolated Systolic Hypertension Among Middle-Aged and Elderly US Hypertensives *Hypertension.*;**37**:869-874  
<http://dx.doi.org/10.1161/01.HYP.37.3.869>  
(<http://hyper.ahajournals.org/content/37/3/869.short#sec-12>)
- Freire EAM , Laís Medeiros Souto2 , Rozana Mesquita Ciconelli,2011, Assessment measures in systemic lupus erythematosus ,[*Rev Bras Reumatol* ;**51**(1):70-80]  
©Elsevier Editora Ltda
- Gao X, Kuo J, Jiang H, Deeb D, Liu Y, Divine G, Chapman RA, Dulchavsky SA, Gautam SC, 2004, Immunomodulatory activity of curcumin: suppression of lymphocyte proliferation, development of cell-mediated cytotoxicity, and cytokine production in vitro.*Biochem Pharmacol*, Jul 1;**68**(1):51-61.
- Gautam SC, Gao X, Dulchavsky S,2007,Immunomodulation by curcumin. *Adv Exp Med Biol*: 595:321-41



- Gerber GS, Brendler CB. 2011, Evaluation of the urologic patient: history, physical examination, and urinalysis. In: Wein AJ, Kavoussi LR, Novick AC, et al., eds. *Campbell-Walsh Urology*. 10th ed. Philadelphia, Pa: Elsevier Saunders; :chap 3.
- Giannouli S, M Voulgarelis, P D Ziakas, A G Tzioufas, 2006, Anaemia in systemic lupus erythematosus: from pathophysiology to clinical assessment, *Ann Rheum Dis*. Feb; **65**(2): 144–148.
- Glasscock R dan Winearls C, 2009, Ageing and the Glomerular Filtration Rate: Truth and Consequences, *Trans Am Clin Climatol Assoc.*; **120**: 419–428. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2744545/>
- Golombick, T., Diamond, T.H., Manoharan, A. and Ramakrishna, R., 2015, The Effect of Curcumin (as Meriva) on Absolute Lymphocyte Count (ALC), NK Cells and T Cell Populations in Patients with Stage 0/1 Chronic Lymphocytic Leukemia. *Journal of Cancer Therapy*, **6**, 566-571. <http://dx.doi.org/10.4236/jct.2015.67061>
- Gordon C & Isenberg D, 2016, *Systemic Lupus Erythematosus*, Oxford University Press, New York, USA
- Greco CM, Ph.D., Claire Nakajima, BA, and Susan Manzi, MD, MPH, 2013, Updated Review of Complementary and Alternative Medicine Treatments for Systemic Lupus Erythematosus, *Curr Rheumatol Rep*. Nov; **15**(11): 378.
- Green, L.W, Kreuter M. W, Deeds S. G, and Patridge K.B. 2000. *Health Promotion Planning An Educational and Environmental Approach Second Edition*. California : Mayfield Publishing Company
- Gupta S, Chiplunkar S, Kim C, Yel L, Gollapudi S. 2003, Effect of age on molecular signaling of TNF-alpha-induced apoptosis in human lymphocytes. *Pubmed*. 2003; **124**(4):503-9.
- Gupta SC, Patchva S, Aggarwal B, 2013, Therapeutic Roles of Curcumin: Lessons Learned from Clinical Trials., *AAPS J*. 2013 Jan; **15**(1): 195–218. Published online 2012 Nov 10. doi: [10.1208/s12248-012-9432-8](https://doi.org/10.1208/s12248-012-9432-8) [www.ncbi.nlm.nih.gov/pmc/articles/PMC3535097/](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3535097/)
- Guzman J, Cardiel MH, Arce-salinas, 1992, Measurement of disease activity in systemic Lupus Erythematosus. Prospective validation of 3 clinical indices. *J Rheumatol*; **19**:1551-1558

- Gvili AG, Leonard Leibovici, Yair Molad, 2013, Elevation of inflammatory markers in patients with systemic lupus erythematosus is associated with poorer outcome, *Biomed & Pharmacother* **67**: 48–52
- Harley JB, James JA, 2006, Epstein-Barr Virus Infection Induce Lupus Autoimmunity, *Bulletin of the NYU Hospital for Joint Diseases* • Volume **64**, Numbers 1 & 2
- Hildebrand J, Muller D, 2004, *Systemic Lupus Erythematosus*, Department of Internal Medicine, University of Wisconsin
- Hlavačková L, Andrea Janegová, Olga Uličná, Pavol Janega, Andrea Černá, and Pavel Babál, 2011, Spice up the hypertension diet - curcumin and piperine prevent remodeling of aorta in experimental L-NAME induced hypertension, *Nutr Metab (Lond)*; **8**: 72, doi: 10.1186/1743-7075-8-72  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3214182/>
- Holmes HM<sup>1</sup>, Murphy PW, Davis TC, Nandy I, Elder CG, Broadwell LH, 1997, Literacy in patients with a chronic disease: systemic lupus erythematosus and the reading level of patient education materials. *J Rheumatol*. Dec;**24**(12):2335-9.
- Howard, C. H., Mayhew, S. L., 2006, The Pharmacist's Role in the Treatment of Systemic Lupus Erythematosus, *US Pharm*; 5:30-48.
- Huang, M. T., Ma, W., Lou, Y. R., Chang, R., Newmark, H., Conney, A. H., 1995, Inhibitory effect of curcumin on tumorigenesis in mice in Pramono, S. (ed) *Curcumin Pharmacology*, Aditya Media: 47-63.
- Hudiyanti, V., Kertia, N., Sumardi, 2012. Effect of Curcuminoid versus Diclofenac Sodium on Monocytes Secretion of Tumor Necrosis Factor-Alpha in Knee Osteoarthritis. *J. Intern Med* **2**(1):27-32.
- Hu M, Du Q, Vancurova I, et al. 2005, Proapoptotic effect of curcumin on human neutrophils: activation of the p38 mitogen-activated protein kinase pathway. *Critical Care Medicine*. ;**33**(11):2571–2578. [PubMed]
- Ibanez D, Gladman DD, Touma Z, Nikpour M, Urowitz MB. 2011, Optimal frequency of visits for patients with systemic lupus erythematosus to measure disease activity over time. *J Rheumatol* ;**38**:60-3. doi:10.3899/jrheum.100575  
<http://www.jrheum.org/content/38/1/60>
- Iqbal, M., Sharma, S.D., Okazaki, Y., Fujisawa, M., and Okada, S., 2003, Dietary



supplementation of curcumin enhances antioxidant and phase II metabolizing enzymes in ddY male mice: possible role in protection against chemical carcinogenesis and toxicity, *Pharmacol. Toxicol.*, **92**, 33-38

Itokawa H, Shi Q, Akiyama T, Morris-Natschke SL, Lee KH. 2008, Recent advances in the investigations of curcuminoids. *Chinese medicine*, 3:1-13

Jacob. A, Rongqian Wu, Mian Zhou, Ping Wang, 2007, Mechanism of the Anti-inflammatory Effect of Curcumin: PPAR- $\gamma$  Activation, *PPAR Res* : **89** 369

Jacobsen S, Petersen J, Ullman S, Junker P, Voss A, Rasmussen JM, *et al.* 1999, Mortality and causes of death of 513 Danish patients with systemic lupus erythematosus. *Scand J Rheumatol*; **28**(2):75-80.

Jagetia GC, Aggarwal BB. 2007, "Spicing up" of the immune system by curcumin. *J of Clin Immunol.*; **27**(1):19–35. [PubMed]

Jang, M.K., Sohn, D.W., Ryu, J.H., 2001. A Curcuminoid and Sesquiterpenes from *Curcuma zedoria* as Inhibitor of Macrophage TNF- $\alpha$  Release. *Planta Med.* **67**:550-52.

Jain SK, Rains J, Croad J, Larson B, Jones K, 2009, Curcumin supplementation lowers TNF- $\alpha$ , IL-6, IL-8, and MCP-1 secretion in high glucose-treated cultured monocytes and blood levels of TNF- $\alpha$ , IL-6, MCP-1, glucose, and glycosylated hemoglobin in diabetic rats., *Antioxid Redox Signal*, Feb; **11**(2): 241–249. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2933148/>

Jayaprakasha, G.K., Jaganmohan, R.L., Sakariah, K.K., 2006. Antioxidant Activities of Curcumin, Demethoxycurcumin and Bisdemethoxycurcumin. *Food Chemistry*. **98** : 720-24

Joe B, Lokesh BR, 1997, Prophylactic and therapeutic effects of n-3 polyunsaturated fatty acids, capsaicin, and curcumin on adjuvant induced arthritis in rats. *J Nutr Biochem* **8**: 397-407.

Jorm AF, 2000, Mental health literacy Public knowledge and beliefs about mental disorders *The British Journ of Psychiatry*, **177** (5) 396-401  
DOI: 10.1192/bjp.177.5.396 <http://bjp.rcpsych.org/content/177/5/396>

Joyce K, Berkebile C, Hastings C, Yarboro C, Yocum D. 1989, Health status and Disease activity in systemic lupus erythematosus. [ cited 2011 Dec 7 ].  
[http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Retrieve&list\\_uids=2487695&dopt=abstractplus](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Retrieve&list_uids=2487695&dopt=abstractplus)

- Jung JH, Soh, MS, Ahn, YH, UmYJ, Jung, JY, Suh, CH, et al., 2016, Thrombocytopenia in Systemic Lupus Erythematosus Clinical Manifestations, Treatment, and Prognosis in 230 Patients, *Medicine (Baltimore)*. 2016 Feb; 95(6): <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4753950/> e2818. doi: [10.1097/MD.0000000000002818](https://doi.org/10.1097/MD.0000000000002818)
- Kang, H. C. et al., 2002, Curcumin inhibits collagen synthesis and hepatic stellate cell activation in vivo and in vitro. *J. Pharm. Pharmacol.*, **54**, 119–126. 58.
- Kaplan MJ. 2011, Neutrophils in the pathogenesis and manifestations of SLE. *Nat Rev Rheumatol*. 2011; **7**:691–9. **PubMed CentralView ArticlePubMedGoogle Scholar**
- Kementrian Kesehatan, 2010, Lima Juta Orang di Dunia Menderita Lupus, Pusat Komunikasi Publik, Sekretariat Jenderal Kementerian Kesehatan RI., <http://www.depkes.go.id/article/print/1073/lima-juta-orang-di-dunia-menderita-lupus.html>
- Kertia, N., Danang, Broto, R., Rahardjo, P., Asdie, A. H., 2000, Increase Quality of Service for Patients with Osteoarthritis by Using the Combination of Curcuminoid and Curcumin's Atsiri Oil in *Abstract of 9<sup>th</sup> Asia Pacific League of Associations for Rheumatology Congress*, Beijing, pp 273
- Khajehdehi P, Zanjanejad B, Aflaki E, Nazarinia M, Azad F, Malekmakan L, Dehghanzadeh GR., 2012, Oral supplementation of turmeric decreases proteinuria, hematuria, and systolic blood pressure in patients suffering from relapsing or refractory lupus nephritis: a randomized and placebo-controlled study. *J Ren Nutr*. Jan; **22**(1):50-7. doi: 10.1053/j.jrn.2011.03.002. Epub 2011 Jul 13. <https://www.ncbi.nlm.nih.gov/pubmed/21742514>
- Khanna S, Pal H, Pandey RM, Handa R., 2004, The relationship between disease activity and quality of life in systemic lupus erythematosus, *Rheumatol (Oxford)* December 1, **43**(12):1536-1540, Epub 2004 Sep 1. <http://rheumatology.oxfordjournals.org/content/43/12/1536>.
- Koh ET, Boey ML, 1994, Late onset lupus: a clinical and immunological study in a predominantly Chinese population. *The J of Rheumatol* [1994, **21**(8):1463-1467]
- Kulkarni SK, Dhir A, Akula KK. 2009, Potentials of curcumin as an antidepressant. *Sci World J* 2009; **9**:1233-1241 <https://www.ncbi.nlm.nih.gov/pubmed/19882093>

- Kumar,P dan Rosenara Beegum. 2007. Systemic Lupus Erythematosus-An atypical presentation 9(4). Kerala: *Medical College Hospital-Alleppey*
- Kurup VP,K, Barios CS, Raju R, Bryon D Johnson, Michael B Levy,Jordan NF 2007, Immune response modulation by curcumin in a latex allergy model, *Clin Mol Allergy*.; **5**: 1.
- Lahita RG, 2004, *Systemic Lupus Erythematosus*, fourth ed, Academic Press, Elsevier p 649
- Lewis EE, W Joseph McCune and Jason S Knight 2016, Neutrophilia in Systemic Lupus Erythematosus As a Potential Indicator of Disease Activity  
*Meeting: ACR/ARHP Annual Meeting (American College of rheumatology)*  
<http://acrabstracts.org/abstract/neutrophilia-in-systemic-lupus-erythematosus-as-a-potential-indicator-of-disease-activity/>
- Lin, C.-C., Lin, H.-Y., Chen, H.-C., Yu, M.-W., and Lee, M.-H., 2009, Stability and characterisation of phospholipid-based curcumin-encapsulated microemulsions, *Food Chemistry*, **116**, 923–928
- Lopresty AL, Hood SD, Drummond PD.2012, Multiple antidepressant potential modes of action of curcumin: a review of its anti-inflammatory, monoaminergic, antioxidant, immune-modulating and neuroprotective effects. *J Psychopharmacol*;**26**(12):1512–1524
- Luo Q, Huang Z, Jianqing Ye, Yating Deng,Le Fang,Xue Li, et al 2016.PD-L1-expressing neutrophils as a novel indicator to assess disease activity and severity of systemic lupus erythematosus,*Arthr Research & Ther* **18**:47. DOI: 10.1186/s13075-016-0942-0
- Manson, Jessica.J., Anisur, Rahman. 2006. *Systemic Lupus Erythematosus*. London: University Collage London  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1459118/>
- Martin AS, 2012,'Non Malignant Leucocyte disorder' in Rodak BF ,Fritsma GA, Keohane E, *Hematology: Clinical Principles and Applications*, ed 4, penerbit Elsevier,pp 408-426
- Maury CP, Teppo AM. 1989,Tumor necrosis factor in the serum of patients with systemic lupus erythematosus. *Arthritis Rheum.*;**32**:146–50. [[PubMed](#)]
- Mc Mahon, M., Hahn, B.H., Skaggs, B.J., 2011. Systemic Lupus Erythematosus and cardiovascular disease. prediction and potential for theurapeutic intervention. *Expert Rev Clin Immunol*. **7**(2):227-241

- Mc Elhone K, Abbott J, 2006, The L-S, A review of health related quality of life in systemic lupus erythematosus, *Lupus* October 1, **15**(10):633-643
- Medina-Rosas J, Gladman DD, Su J, Sabapathy A, Urowitz MB, Touma Z., 2015, Utility of untimed single urine protein/creatinine ratio as a substitute for 24-h proteinuria for assessment of proteinuria in systemic lupus erythematosus. *Arthritis Res Ther.* Oct 24; **17**:296. doi: 10.1186/s13075-015-0808-x  
<https://www.ncbi.nlm.nih.gov/pubmed/26497948>
- Menon V.P., Sudheer A.R. ,2007, Antioxidant and anti-inflammatory properties of curcumin. *Adv. Exp. Med. Biol.*, **595**, 105–125. [PubMed]
- Mills, J. A., 1994, Systemic Lupus Erythematosus, *N Eng J Med*; **330**:1871-9.
- Mirzayan, M. J., Schmidt, R. E and Witte, T., 2000, Prognostic parameter for flare in systemic lupus erythematosus, *Rheumatology (Oxford)*; **39**: 1316-9.
- Moghadamtousi SZ et al, 2014, A Review on Antibacterial, Antiviral, and Antifungal Activity of Curcumin, *BioMed Research International* Volume 2014 (2014), Article ID 186864, 12 pages  
<http://dx.doi.org/10.1155/2014/186864>
- Mok, C. C and Lau, C. S, 2003, Review: Pathogenesis of systemic lupus erythematosus, *J Clin Pathol*; **56**:481-90.
- Navarra SV, Guzmán RM, Gallacher AE, 2011, for the BLISS-52 Study Group. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. *Lancet*; **377**: 721-731
- Nawaz, A., Khan, G.M., Hussain, A., Ahmad, A., Khan, A., Safdar, M., 2011. Curcumin : A Natural Product Of Biological Importance. *Gomal University J of Research.* **27**(1) : 7-14.
- NN. *How to Score the RAND SF-36 Questionnaire*. [cited 2012 Jan 4]. Available From : [http://www.chiro.org/LINKS/OUTCOME/How\\_to\\_score\\_the\\_SF-36.pdf](http://www.chiro.org/LINKS/OUTCOME/How_to_score_the_SF-36.pdf)
- Nahid Janoudi and Ekhlas Samir Bardisi ,2012. Haematological Manifestations in Systemic Lupus Erythematosus, Systemic Lupus Erythematosus, Dr Hani Almoallim (Ed.), ISBN: 978-953-51-0266-3, InTech, Available from: <http://www.intechopen.com/books/systemic-lupus->

erythematosus/haematologicalmanifestations-in-systemic-lupus-  
erythematosus

Neal R, Quattro KD, Ortiz EZ, Quismorio FP, 2014, Childhood-Onset and Adult-Onset Systemic Lupus Erythematosus: Distinctions in an Underserved Ethnic Minority Cohort, presented on 2014 ACR/ARHP Annual Meeting.  
<http://acrabstracts.org/abstract/childhood-onset-and-adult-onset-systemic-lupus-erythematosus-distinctions-in-an-underserved-ethnic-minority-cohort/>

Neto NSR, Carvalho JF, 2009, The use of inflammatory laboratory tests in rheumatology, *Rev. Bras. Reumatol.* vol. **49** no.4 São Paulo July/Aug. 2009

NN. 2009, *Anxiety And Depression Lower Quality of Life In Majority Of Systemic Lupus*. [cited 2012 July 30]. Available from : <http://www.eular.org/>

Nutman TB, 2007, Evaluation and differential diagnosis of marked, persistent eosinophilia, *Immunol Allergy Clin North Am.* Aug; 27(3): 529–549. doi: [10.1016/j.iac.2007.07.008](https://doi.org/10.1016/j.iac.2007.07.008)  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2099264/>

Oehadian A, 2008, Kelainan Darah pada Lupus Eritematosus Sistemik, Diajukan pada *Simposium Lupus Eritematosus Sistemik untuk awam* pada tanggal 17 Februari 2008, RS Hasan Sadikin Bandung

Osei-Bimpong A, Meek JH, Lewis SM, 2007, ESR or CRP? A comparison of their clinical utility. *Hematology* ;**12**(4):353–7

Panahi Y, Kianpour P, Mohtashami R, Jafari R, Simental-Mendía LE, Sahebkar 2016, Curcumin Lowers Serum Lipids and Uric Acid in Subjects With Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial., *J Cardiovasc Pharmacol.*; **68**(3):223-9. doi: 10.1097/FJC.0000000000000406.,  
<https://www.ncbi.nlm.nih.gov/pubmed/27124606>

Patell R, Theil K, Lichtin A, 2016, Erythrocytosis due to presumed polycythemia vera, *CCJM*; **83**(9):648-653. 10.3949/ccjm.83a.15154  
<http://www.ccjm.org/cme/cme/article/erythrocytosis-due-to-presumed-polycythemia-vera/68e27e7bfa5c18702e63c66e05845419.html>

Pathare YS dan Wagh. VD, 2012, Herbal Medicines and Nutritional Supplements used in the treatment of Glaucoma, a Review, *Res J of Pharmaceutical Biol and Chem Sciences*, Vol **3** Issue 1: 331-339,  
[http://www.rjpbcs.com/pdf/2012\\_3\(1\)/42.pdf](http://www.rjpbcs.com/pdf/2012_3(1)/42.pdf)

Perhimpunan Rematologi Indonesia, 2011, *Diagnosis dan Pengelolaan Lupus Eritematosus Sistemik*, Perhimpunan Reumatologi Indonesia

Petri M, 2016, *Urinalysis*, The John Hopkins Lupus Centre  
<<https://www.hopkinslupus.org/lupus-treatment/>>

Pisetsky, DS, 2008, 'Systemic Lupus Erythematosus', dalam Klippel JH, Stone JH, Crofford LJ, White PH, Primer on the Rheumatic Disease, ed 13, Springer, New York USA, p 319-337

Pinto E, 2007, Blood Pressure and Ageing, *Postgrad Med J*. 2007 Feb; **83**(976): 109–114. doi: 10.1136/pgmj.2006.048371  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2805932/>

Popa C, Netea MG, van Riel PL, van der Meer JW, Stalenhoef AF, 2007, The role of TNF-alpha in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk, *J Lipid Res*. Apr; **48**(4):751-62.

Postal M, Aline Tamires Lapa, Nailú Angélica Sinicato, Karina de Oliveira Pelicari, Fernando Augusto Peres1, Lilian Tereza Lavras Costallat, et al, 2016, Depressive symptoms are associated with tumor necrosis factor alpha in systemic lupus erythematosus, *Journ of Neuroinflam* **13**:5

Prakash P, Misra A, Surin WR, Jain M, Bhatta RS, Pal R, Raj K, Barthwal MK, Dikshit M. 2011, Anti-platelet effects of Curcuma oil in experimental models of myocardial ischemia-reperfusion and thrombosis. *Thromb Res*. Feb; **127**(2):111-8. doi: 10.1016/j.thromres.2010.11.007. Epub 2010 Dec 8. <https://www.ncbi.nlm.nih.gov/pubmed/21144557>

Purwakusumah, E.D., Y. Lestari, M. Rahminiwati, M. Ghulamahdi, B. Barus dan M. Machmud, MT. 2008. Menjadikan temulawak sebagai bahan baku utama industri berbasis kreatif yang berdaya saing. Pusat Studi Biofarmaka LPPM-IPB. E-mail: [bfarmaka@gmail.com](mailto:bfarmaka@gmail.com), 24 hlm.

Rahardjo, M., 2010. Penerapan SOP Budidaya untuk Mendukung Temulawak Sebagai Bahan Baku Obat Potensial. *Perspektif*. **9**(2) : 78-93.

Rahman A, Isenberg DA. 2008, Systemic lupus erythematosus. *N Engl J Med*. **358**(9):929-39. [View Abstract]

Rukayadi, Y., Yong, D., Hwang, J.K., 2006. In Vitro Anticandidal Activity of Xanthorrhizol Isolated from *Curcuma xanthorrhiza* Roxb. *J of Antimicrob Chemother*. **57** : 1231-34.



- Rinaldy S, Doria A, Salaffi F, Ermani M, Laccarino L, Ghirardello A, et al, 2004, Health-related quality of life in Italian patients with systemic lupus erythematosus. I. Relationship between physical and mental dimension and impact of age, *Rheumatology* (Oxford) December 1, **43**(12):1574-1579
- Rivero SJ, Díaz-Jouanen E, Alarcón-Segovia D.1978, Lymphopenia in systemic lupus erythematosus. Clinical, diagnostic, and prognostic significance. *Arthritis Rheum*; **21**:295-305.
- Ruslay, S., Abas, F., Shaari, K., Zainal, Z. Maulidiani, Sirat, H., Israf, D.A., Lajis, N.H, 2007, Characterization of the components present in the active fractions of health gingers (*Curcuma xanthorrhiza* and *Zingiber zerumbet*) by HPLC–DAD–ESIMS, *Food chemistry*, **104**(3), 1183-1191
- Ryan,DE and Levin W, 1993, Purification and Characterization of Hepatic Microsomal Cytochrome P-450, *Pharmacol and Therapeutic*,**45**: 153-239
- Sabry A, Sheashaa H, El-Husseini A, Mahmoud K, Eldahshan KF, George SK, et al.2006, Proinflammatory cytokines (TNF-alpha and IL-6) in Egyptian patients with SLE: its correlation with disease activity. *Cytokine*. ;**35**:148–53.
- Sahin, 2009, Mycophenolate Mofetil in the Treatment of Systemic Lupus Erythematosus, *Eurasian J Med*. Dec; 41(3): 180–185.
- Samuhasaneeto, S., Thong-Ngam, D., Kulaputana, O., Suyasunanont, D., Klaikeaw, N., 2009. Curcumin Decreased Oxidative Stress, Inhibited NFKB Activation, and Improved Liver Pathology in Ethanol-Induced Liver Injury in Rats., *J.of Biomed and Biotech*. 1-8.
- Sandur SK, Pandey MK, Sung B, Ahn KS, Murakami A, Sethi G, Limtrakul P, Badmaev V, Aggarwal B. 2007, Curcumin Demethoxycurcumin, Bisdemethoxycurcumin, Tetrahydrocurcumin and turmerones differentially regulate anti inflammatory and anti proliferative response through a ROS independent mechanism. *Carcinogenesis*.; **28** (8):1765-73.
- Sanmukhani J, Satodia V, Trivedi J, 2014,. Efficacy and safety of curcumin in major depressive disorder: a randomized controlled trial. *Phytother Res*. ;**28**(4):579-585. (PubMed)
- Satoskar RR, Shah SJ, Shenoy SG.,1986, Evaluation of anti-inflammatory property of curcumin (diferuloyl methane) in patients with postoperative inflammation. *Int J Clin Pharmacol Ther Toxicol*. ;**24**(12):651-654. (PubMed)

- Sayed Khalda, Bayoumi FS, Elgengehy FT, Abdallah SO, Ahmed HH, Eissa E, 2016, The role of microRNA-31 and microRNA-21 as regulatory biomarkers in the activation of T lymphocytes of Egyptian lupus patients, *Rheumatology International*, Volume **36**, Issue 11, pp 1617–1625
- Schur, P. H, 1989, Clinical Features of SLE in Kelley, W. N., Harris, E. D., Ruddy, and Sledge, C. B, *Textbook of Rheumatology 3<sup>rd</sup> ed*, W. B. Saunders Co., 1101-29.
- Schur PH, Massarroti EM, 2012, *Lupus Erythematosus : Clinical Evaluation and Treatment*, Springer, New York, USA
- Shahin D, 2011, Thrombocytopenia and leukocytosis are independent predictors of hyperprolactinemia in systemic lupus erythematosus patients, *The Egypt Rheumatolog* Volume **33**, Issue 2, Pages 77–83
- Shalaby MA dan Hammouda A, 2014, Nephroprotective, Diuretic and Antioxidant Effects of Some Medicinal Herbs in Gentamicin-Nephrotoxic Rats, *J Intercult Ethnopharmacol.* ; **3**(1): 1-8  
doi: 10.5455/jice.20131130022009
- Sharp VJ, Barnes KT, Errickson BA, 2013, Assessment of asymptomatic microscopic hematuria in adults. *Am Fam Physician.*; **88**(11):747-54.  
<https://www.ncbi.nlm.nih.gov/pubmed/24364522>
- Shin SK, Ha TY, McGregor RA, Choi MS., 2011, Long-term curcumin administration protects against atherosclerosis via hepatic regulation of lipoprotein cholesterol metabolism. *Mol Nutr Food Res*; **55**:1829–1840.
- Shiel, William C. 2008, “Sedimentation Rate.” *Medicine Net.com*. 25 April 2008. MedicineNet, Inc. 12 July 2009.  
<[http://www.medicinenet.com/sedimentation\\_rate/article.htm](http://www.medicinenet.com/sedimentation_rate/article.htm)>.
- Shukla, Y. and Arora, A., 2003, Suppression of altered hepatic foci development by curcumin in Wistar rats. *Nutr. Cancer*, 2003, **45**, 53–59
- Snowdon J, 2001, Prevalence of depression in old age , *The British J of Psychiatry*, **178** (5) 476-477; DOI: 10.1192/bjp.178.5.476  
<http://bjp.rcpsych.org/content/178/5/476>
- Song, E. K. Cho H, Kim DS, Kim NY, An NH, Kim DA et al., 2001, Diarylheptanoids

with free radical scavenging and hepatoprotective activity in vitro from *Curcuma longa*. *Planta Med.*, **67**, 876–877

Srivastava, R., Dikshit, M., Srimal, R. C. and Dhawan, B. N., 1985, Antithrombotic effect of curcumin. *Thromb. Res.*, **40**, 413–417

Staud R, M Rodriguez, R Patel, M Satoh, H Richards, W Reeves; 2006, *Psychophysical characterization of patients with systemic lupus erythematosus or fibromyalgia*, University of Florida, Gainesville, FL

Steinberg AD, Steinberg SC. 1991, Long term preservation of renal function in patients with Lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. *Arthritis Rheum*; **34**:945-50

Stojan D, Fang H, Magder L, Petri M, 2013, Erythrocyte sedimentation rate is a predictor of renal and overall SLE disease activity. *Lupus*. Jul; **22**(8):827-34. doi: 10.1177/0961203313492578. Epub 2013 Jun 11.

Sudarsono, Pudjoarinto, A., Gunawan, D., Wahyuono, S., Donatus, I. A., Djrajad, M., Wibowo, S., Ngatidjan., 1996, *Tumbuhan Obat, Pusat Penelitian Obat Tradisional*. Universitas Gadjah Mada Yogyakarta, 54-8.

Sutcliffe N, Clarke AE, Levinton C, Frost C, Gordon C, Isenberg DA. 2000, Associates of health status in patients with systemic lupus erythematosus. . [cited 2011 Oct 8]. Available from : <http://www.ncbi.nlm.nih.gov/pubmed/10555890>

Studnicka-Benke A, Steiner G, Petera P, Smolen JS. 1996, Tumour necrosis factor Alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus. *Br J Rheumatol*. 1996; **35**:1067–74. [PubMed]

Sudjarwo, A.S., 2004, The Signal Transduction of Curcumin as Antiinflammatory Agent in Cultured Fibroblast, *Jurnal Kedokteran YARSI*, **12**(3), 5-6

Sulistyoningrum, H., 2008, Efek Gastroprotektor Temulawak (*Curcuma Xanthorrhiza* Roxb.), *Skripsi*, Fakultas Kedokteran, Universitas Muhammadiyah Surakarta, Surakarta.

Syamal K, D., Zhang, L and Xu, L., 2005, Review: T-helper cell intrinsic defects in lupus that break peripheral tolerance to nuclear autoantigens, *J Mol Med*; **83**: 267-78.

- Thomas JR, Irene Blanco, and Chaim Putterman, 2011, Urinary Biomarkers in Lupus Nephritis, *Clin Rev Allergy Immunol.*; **40**(3): 138–150.  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2917506/>
- Thumboo, J, Fong KY, Ng TP, et al. 1999, Validation of the MOS SF-36 for quality of life assessment of patients with systemic lupus erythematosus in Singapore. *J Rheumatol* ; **26**: 97-102.
- Trujillo J, Chirino YI, Eduardo Molina-Jijón, Andérica-Romero AC, Edilia Tapia, and José Pedraza-Chaverri, 2013, Renoprotective effect of the antioxidant curcumin: Recent findings, *Redox Biol.* ; **1**(1): 448–456
- Uehara S, Yasusa I, Takeya K, Itokawa H, Iitaka Y. 1990, New bisabolane sesquiterpenoids from the rhizomes of *Curcuma xanthorrhiza* (Zingiberaceae). *Chem Pharm Bull* , **38**(1):261-263
- Ulutas, Ozkan *et al.* 2011. Systemic Lupus Erythematosus Associated Gastrointestinal System Vasculopathy in a Patient with Lupus Nephropathy. *J Turk Neph Dial Transpl*, **20** (3): 295-298. doi: 10.5262/tndt.2011.1003.15
- Unnikrishnan MK, Rao MN. 1995, Inhibition of nitrite induced oxidation of hemoglobin by curcuminoids. *Pharmazie*. Jul; **50**(7):490-2.
- Utsinger PD. 1976, Relationship of lymphocytotoxic antibodies to lymphopenia and parameters of disease activity in systemic lupus erythematosus. *J Rheumatol* ; **3**: 175–85.
- Velo Garcia A, Castro SG, Isenberg DA 2016, The Diagnosis and Management of the Haematologic manifestations of lupus, *J. of Autoimmunity* **vol 74** 139-160, <http://dxdoi.org/10.1016/j.jaut.2016.07.001>  
<http://www.sciencedirect.com/science/article/pii/S0896841116300993>
- Vilá LM, Alarcón GS, McGwin G Jr, Gerald McGwin Jr, Holly M. Bastian, Barri J. Fessler, John D. Reveille *et al.* 2006, Systemic lupus erythematosus in a multiethnic US cohort, XXXVII: association of lymphopenia with clinical manifestations, serologic abnormalities, disease activity, and damage accrual. *Arthritis Rheum* ; **55**:799.
- Varalakshmi, Ch, Ali, A.M., Pardhasaradhi, B.V.V., Srivastava, R.M., Singh S., Khar A., 2008, Immunomodulatory effects of curcumin: In-vivo, *Int Immunopharm* **8**, 688–700
- Venkatesan M, Durairaj Punithavathi, Venkatesan Arumugam, 2000, Curcumin

prevents adriamycin nephrotoxicity in rats, *Br J of Pharmacol*, **129**, 231–234  
DOI: [10.1038/sj.bjp.0703067](https://doi.org/10.1038/sj.bjp.0703067)

<http://onlinelibrary.wiley.com/doi/10.1038/sj.bjp.0703067/full>

Vermoken AJM, Zhu J, Van de Ven WJ, Andre E, 2012<sup>a</sup>, Wiley Periodicals, Inc.  
*American Journal of Hematol* <http://wileyonlinelibrary.com/cgi-bin/jhome/35105>

Vermoken AJ, Zhu J, Van de Ven WJ, Andre E, 2012<sup>b</sup>. Curcumin for monoclonal gammopathies. What can we hope for, what should we fear? *Crit Rev Oncol Hematol* 2012 doi: 10.1016/j.critrevonc..04.005

Waldheim, Eva. 2013, *Self Reported Pain in SLE*, Karolinka Instituted, Sweden

Wallace, Daniel J. 2007. *The Lupus Book*. Diterjemahkan oleh Wiratama, C. Yogyakarta: B-first

Wallace DJ dan Hahn BH, 2007. *Dubois Lupus erythematosus*, 7<sup>th</sup> ed, Lippincott William and Wilkins, USA

Wang C, Mayo NE, Fortin PR, 2001, The relationship between health related quality of life and disease activity and damage in systemic lupus erythematosus, *J Rheumatol*. Mar; **28**(3):525-32.

Wahlström B, Blenow G, 1978, A study on the fate of curcumin in the rat. *Acta Pharmacol Toxicol* (Copenh) **43**(2):86-92.  
<https://www.ncbi.nlm.nih.gov/pubmed/696348>

Weckerle CE, Niewold TB. 2011, The unexplained female predominance of systemic lupus erythematosus: clues from genetic and cytokine studies. *Clin Rev Allergy Immunol*. Feb; **40**(1):42-9. doi: 10.1007/s12016-009-8192-4.

Weckerle CE, Imbuka D, Franek, Jennifer A. Kelly, Marissa Kumabe, Judith A. et al, 2012, Large Scale Analysis of Tumor Necrosis Factor Alpha Levels in Systemic Lupus Erythematosus, *Arthritis Rheum*. Sep; **64**(9): 2947–2952.

Wysenbeek. Pick, Sella, Beigel, Yeshurun M.D. 1980, Eosinophilic pleural effusion with high anti-DNA activity as a manifestation of systemic lupus erythematosus *Postgrad Med Journal* **56**, 57-58 Downloaded from <http://pmj.bmj.com/> on November 3, 2016 - Published by group.bmj.com

Wilmana, P.F., Gunawan, S.G., 2012. Analgesik-antipiretik, Analgesik. Antiinflamasi

nonsteroid dan Obat Gangguan Sendi Lainnya : *Farmakologi dan Terapi*. Edisi 5. Jakarta: Departemen Farmakologi dan Terapetik FK UI pp. 230-237

Witt, M; D. Zecher; J. Anders. 2006. Gastrointestinal Manifestations Associated With Systemic Lupus Erythematosus. *J Med Res*. **11**: 253-260

Yang, P., Zhang, Y., Ping, Lv and Gao, X., 2007, Apoptosis of murin lupus T cells induced by the selective cyclooxygenase-2 inhibitor celecoxib: Molecular mechanism and therapeutic potential, *Intern Immunopharm*; **7**: 1414-21.

Yayasan Lupus Indonesia. 2011. *Systemic Lupus Erythematosus*. Jakarta: YLI (<http://yayasanlupusindonesia.org/category/buku-lupus/>), diakses tanggal 3 September 2013

Yasdany J dan Yelin Edward, 2010, Health-Related Quality of Life and Employment Among Persons with Systemic Lupus Erythematosus, *Rheum Dis Clin North Am* **36**(1):15-32

Yee CS, McElhone K, Teh LS, Gordon C, 2009, Assessment of disease activity and quality of life in systemic lupus erythematosus - New aspects. *Best Pract Res Clin Rheumatol*. Aug;**23**(4):457-67. doi: 10.1016/j.berh.2009.01.007.

Yu JJ, Pei LB, Zhang Y, Wen ZY, Yang JL. 2015, Chronic supplementation of curcumin enhances the efficacy of antidepressants in major depressive disorder: a randomized, double-blind, placebo-controlled pilot study. *J Clin Psychopharmacol*.;**35**(4):406-410. (PubMed)

Z. Zakeri, M. Shakiba, B. Narouie, N. Mladkova, M. GhasemiRad, and A. Khosravi, 2012, "Prevalence of depression and depressive symptoms in patients with systemic lupus erythematosus: Iranian experience," *Rheumatology Intern.*, vol. **32**, no. 5, pp. 1179–1187.

Zhu, L.J., Yang., X.Y., Yu, X.Q., 2010. Anti-TNF-alpha Therapies in Systemic Lupus Erythematosus. *J Biomed Biotech* :1-8.

Zhu DJ, 2016, Curcumin Partly Ameliorates Irinotecan-Induced Diarrhea and Synergistically Promotes Apoptosis in Colorectal Cancer Through Mediating Oxidative Stress *Oncotarget*. Jul 14.

Zhang Z, Kelly Maurer, Juan C. Perin, Li Song, and Kathleen E. Sullivan, 2010, Cytokine-Induced Monocyte Characteristics in SLE, *J of Biomed and Biotech* , Article ID 507475, 13 pages <http://dx.doi.org/10.1155/2010/507475>



Ziakas PD Giannouli S,Zintzaras E,Tzioufas AG,Voulgaleris M,2005, Lupus thrombocytopenia: clinical implications and prognostic significance

, *Ann Rheum Dis* ;**64**:1366-1369 doi:10.1136/ard.2004.033100  
<http://ard.bmj.com/content/64/9/1366.full>

Zwaving JH, Bos R.1992, Analysis of the essential oils of five *Curcuma* species.  
*Flavour and Fragrance Journal*, **7**:19-22